-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The fifth batch of collectively-collected varieties was outflowed, involving 60 varieties and 207 product specifications.
Qilu Pharmaceutical has 10 over-rated varieties listed.
On April 14-15, Qilu Pharmaceutical's ropivacaine hydrochloride injection passed the consistency evaluation, and brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved.
At present, Qilu Pharmaceutical ranks first in the evaluation list with 64 varieties.
A large number of varieties are on the way of evaluation.
41 new classification varieties are listed on the market and 22 varieties are under review.
The competition among the 10 varieties to be collected is fierce.
Qilu Pharmaceutical will compete with Zhengda Tianqing, Yangtze River, Hengrui.
.
.
Qilu Pharmaceutical has 10 over-rated varieties listed.
On April 14-15, Qilu Pharmaceutical's ropivacaine hydrochloride injection passed the consistency evaluation, and brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved.
At present, Qilu Pharmaceutical ranks first in the evaluation list with 64 varieties.
A large number of varieties are on the way of evaluation.
41 new classification varieties are listed on the market and 22 varieties are under review.
The competition among the 10 varieties to be collected is fierce.
Qilu Pharmaceutical will compete with Zhengda Tianqing, Yangtze River, Hengrui.
.
.
Take down two major varieties! 64 over-reviewed varieties
On April 14-15, the NMPA official website showed that Qilu Pharmaceutical’s ropivacaine hydrochloride injection passed the consistency evaluation, and two varieties of brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved for marketing.
.
.
Ropivacaine Hydrochloride Injection is a new long-acting amide local anesthetic developed by AstraZeneca, and it is the leading drug in the local anesthetic market.
According to data from Menet.
com, the sales of terminal ropivacaine injections in public medical institutions in China exceeded 1.
1 billion yuan in 2019.
Prior to this, the ropivacaine hydrochloride injections of Renfu Pharmaceutical, Shisiyao and Jiabo Pharmaceutical have been reviewed.
According to data from Menet.
com, the sales of terminal ropivacaine injections in public medical institutions in China exceeded 1.
1 billion yuan in 2019.
Prior to this, the ropivacaine hydrochloride injections of Renfu Pharmaceutical, Shisiyao and Jiabo Pharmaceutical have been reviewed.
Brimonidine tartrate eye drops have been approved by 3 domestic companies before, but no company has reviewed it.
After the approval of production this time, Qilu Pharmaceutical became the first company to pass the evaluation of this product.
Emtricitabine tenofovir tablets is a blockbuster anti-AIDS drug developed by Gilead, with global sales of 1.
448 billion US dollars in 2020.
There are 4 companies in the domestic market including Gilead, Zhengda Tianqing, Anhui Baker and Haisco Approved, Qilu Pharmaceutical is the fourth domestic manufacturer of this product.
After the approval of production this time, Qilu Pharmaceutical became the first company to pass the evaluation of this product.
Emtricitabine tenofovir tablets is a blockbuster anti-AIDS drug developed by Gilead, with global sales of 1.
448 billion US dollars in 2020.
There are 4 companies in the domestic market including Gilead, Zhengda Tianqing, Anhui Baker and Haisco Approved, Qilu Pharmaceutical is the fourth domestic manufacturer of this product.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, Qilu Pharmaceutical currently has 64 varieties (116 product specifications) passed or deemed to have passed the consistency evaluation.
Among them, 32 varieties are the first domestic companies to be evaluated, and 17 varieties are injections.
In addition, aprepitant capsules, emtricitabine capsules, metformin vildagliptin tablets, warfarin sodium tablets, risperidone orally disintegrating tablets, isoladine maleate tablets, piperacillil capsules, triflux 13 varieties including uridine tipipyrimidine tablets, cefprozil granules, ondansetron hydrochloride tablets, ondansetron hydrochloride injection, exemestane tablets, brimonidine tartrate eye drops, etc.
are temporarily exclusive to Qilu Pharmaceutical Comment.
com, Qilu Pharmaceutical currently has 64 varieties (116 product specifications) passed or deemed to have passed the consistency evaluation.
Among them, 32 varieties are the first domestic companies to be evaluated, and 17 varieties are injections.
In addition, aprepitant capsules, emtricitabine capsules, metformin vildagliptin tablets, warfarin sodium tablets, risperidone orally disintegrating tablets, isoladine maleate tablets, piperacillil capsules, triflux 13 varieties including uridine tipipyrimidine tablets, cefprozil granules, ondansetron hydrochloride tablets, ondansetron hydrochloride injection, exemestane tablets, brimonidine tartrate eye drops, etc.
are temporarily exclusive to Qilu Pharmaceutical Comment.
It is worth mentioning that Qilu Pharmaceutical’s number of over-rated products has long led domestic companies.
The second-ranked China Biopharmaceutical has 57 products (85 product specifications) over-rated, and Yangzijiang Pharmaceutical Group has 55 products (74 products).
Product regulations) ranked third.
The second-ranked China Biopharmaceutical has 57 products (85 product specifications) over-rated, and Yangzijiang Pharmaceutical Group has 55 products (74 products).
Product regulations) ranked third.
With a large group of over-reviewed varieties, Qilu Pharmaceutical has achieved fruitful results in national procurement.
Among the four batches of drug procurement carried out by the country, Qilu Pharmaceutical has won the bids for 5, 4, 8 and 6 varieties respectively, and a total of 23 varieties have won the bid, and the number of winning bids is the largest.
Among the four batches of drug procurement carried out by the country, Qilu Pharmaceutical has won the bids for 5, 4, 8 and 6 varieties respectively, and a total of 23 varieties have won the bid, and the number of winning bids is the largest.
41 new products are on the way, 22 consistency evaluation varieties are under review
With years of hard work in the field of generic drugs, Qilu Pharmaceutical has ushered in an intensive harvest period for new product approvals.
Many varieties in the product line are expected to be approved for listing in the past two years, which will help Qilu Pharmaceutical to firmly sit on the throne of the "first brother in review".
Many varieties in the product line are expected to be approved for listing in the past two years, which will help Qilu Pharmaceutical to firmly sit on the throne of the "first brother in review".
According to data from Minai.
com, Qilu Pharmaceuticals has 41 varieties (73 acceptance numbers) of generic drugs under review under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production.
In terms of supplementary applications for consistency evaluation, Qilu Pharmaceutical has 22 varieties (35 acceptance numbers) under review and approval.
com, Qilu Pharmaceuticals has 41 varieties (73 acceptance numbers) of generic drugs under review under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production.
In terms of supplementary applications for consistency evaluation, Qilu Pharmaceutical has 22 varieties (35 acceptance numbers) under review and approval.
Qilu Pharmaceutical's varieties of consistency evaluation (including new classification) under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
10 varieties are planned to be collected collectively, against Zhengda Tianqing, Yangtze River.
.
.
.
.
On April 15th, the fifth batch of collectively-collected varieties was released, involving 207 varieties of 60 varieties.
Qilu Pharmaceutical, known as the "price killer", has 10 over-reviewed products on the list this time, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglide Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection and ropivacaine hydrochloride injection.
Among them, 8 varieties are injections.
Qilu Pharmaceutical, known as the "price killer", has 10 over-reviewed products on the list this time, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglide Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection and ropivacaine hydrochloride injection.
Among them, 8 varieties are injections.
The competitive landscape of the fifth batch of Qilu Pharmaceuticals to be collected
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Among the 10 varieties, 8 varieties correspond to generic name drugs in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019.
The terminal sales exceeded 1 billion yuan, respectively.
It is oxaliplatin, isosorbide mononitrate, docetaxel, palonosetron, ceftriaxone, ceftazidime, gemcitabine, ropivacaine.
Among them, the terminal sales of docetaxel injection and ceftazidime for injection in China's public medical institutions exceeded 4 billion yuan and 6 billion yuan respectively in 2019.
The terminal sales exceeded 1 billion yuan, respectively.
It is oxaliplatin, isosorbide mononitrate, docetaxel, palonosetron, ceftriaxone, ceftazidime, gemcitabine, ropivacaine.
Among them, the terminal sales of docetaxel injection and ceftazidime for injection in China's public medical institutions exceeded 4 billion yuan and 6 billion yuan respectively in 2019.
Qilu Pharmaceutical's oxaliplatin injection and saxagliptin tablets were approved for production in 2020 and 2021 respectively, and the market is waiting to be developed.
The remaining 8 varieties have been supplemented by consistency evaluation and have been on the market for many years.
The remaining 8 varieties have been supplemented by consistency evaluation and have been on the market for many years.
In terms of competition, 4 companies have reviewed the 3 varieties, 5 companies have reviewed the 5 varieties, and 3 varieties of Zhengda Tianqing and Yangtze River are listed.
In addition, although Qilu Pharmaceutical and Lepu Pharmaceuticals are the only companies that have reviewed isosorbide mononitrate sustained-release tablets, the isosorbide mononitrate sustained-release capsules of Rundu Pharmaceutical and Heyuan Pharmaceutical have also been reviewed.
Generally speaking, the current competition is fierce, and as time goes by, from the publication of the collection catalogue to the opening of bids, there will be many companies reviewing each category.
In addition, although Qilu Pharmaceutical and Lepu Pharmaceuticals are the only companies that have reviewed isosorbide mononitrate sustained-release tablets, the isosorbide mononitrate sustained-release capsules of Rundu Pharmaceutical and Heyuan Pharmaceutical have also been reviewed.
Generally speaking, the current competition is fierce, and as time goes by, from the publication of the collection catalogue to the opening of bids, there will be many companies reviewing each category.
Data source: Mi Neiwang database
Note: The statistics are as of April 15th, if there are any omissions, please correct me!
The fifth batch of collectively-collected varieties was outflowed, involving 60 varieties and 207 product specifications.
Qilu Pharmaceutical has 10 over-rated varieties listed.
On April 14-15, Qilu Pharmaceutical's ropivacaine hydrochloride injection passed the consistency evaluation, and brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved.
At present, Qilu Pharmaceutical ranks first in the evaluation list with 64 varieties.
A large number of varieties are on the way of evaluation.
41 new classification varieties are listed on the market and 22 varieties are under review.
The competition among the 10 varieties to be collected is fierce.
Qilu Pharmaceutical will compete with Zhengda Tianqing, Yangtze River, Hengrui.
.
.
Qilu Pharmaceutical has 10 over-rated varieties listed.
On April 14-15, Qilu Pharmaceutical's ropivacaine hydrochloride injection passed the consistency evaluation, and brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved.
At present, Qilu Pharmaceutical ranks first in the evaluation list with 64 varieties.
A large number of varieties are on the way of evaluation.
41 new classification varieties are listed on the market and 22 varieties are under review.
The competition among the 10 varieties to be collected is fierce.
Qilu Pharmaceutical will compete with Zhengda Tianqing, Yangtze River, Hengrui.
.
.
Take down two major varieties! 64 over-reviewed varieties
On April 14-15, the NMPA official website showed that Qilu Pharmaceutical’s ropivacaine hydrochloride injection passed the consistency evaluation, and two varieties of brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved for marketing.
.
.
Ropivacaine Hydrochloride Injection is a new long-acting amide local anesthetic developed by AstraZeneca, and it is the leading drug in the local anesthetic market.
According to data from Menet.
com, the sales of terminal ropivacaine injections in public medical institutions in China exceeded 1.
1 billion yuan in 2019.
Prior to this, the ropivacaine hydrochloride injections of Renfu Pharmaceutical, Shisiyao and Jiabo Pharmaceutical have been reviewed.
According to data from Menet.
com, the sales of terminal ropivacaine injections in public medical institutions in China exceeded 1.
1 billion yuan in 2019.
Prior to this, the ropivacaine hydrochloride injections of Renfu Pharmaceutical, Shisiyao and Jiabo Pharmaceutical have been reviewed.
Brimonidine tartrate eye drops have been approved by 3 domestic companies before, but no company has reviewed it.
After the approval of production this time, Qilu Pharmaceutical became the first company to pass the evaluation of this product.
Emtricitabine tenofovir tablets is a blockbuster anti-AIDS drug developed by Gilead, with global sales of 1.
448 billion US dollars in 2020.
There are 4 companies in the domestic market including Gilead, Zhengda Tianqing, Anhui Baker and Haisco Approved, Qilu Pharmaceutical is the fourth domestic manufacturer of this product.
After the approval of production this time, Qilu Pharmaceutical became the first company to pass the evaluation of this product.
Emtricitabine tenofovir tablets is a blockbuster anti-AIDS drug developed by Gilead, with global sales of 1.
448 billion US dollars in 2020.
There are 4 companies in the domestic market including Gilead, Zhengda Tianqing, Anhui Baker and Haisco Approved, Qilu Pharmaceutical is the fourth domestic manufacturer of this product.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, Qilu Pharmaceutical currently has 64 varieties (116 product specifications) passed or deemed to have passed the consistency evaluation.
Among them, 32 varieties are the first domestic companies to be evaluated, and 17 varieties are injections.
In addition, aprepitant capsules, emtricitabine capsules, metformin vildagliptin tablets, warfarin sodium tablets, risperidone orally disintegrating tablets, isoladine maleate tablets, piperacillil capsules, triflux 13 varieties including uridine tipipyrimidine tablets, cefprozil granules, ondansetron hydrochloride tablets, ondansetron hydrochloride injection, exemestane tablets, brimonidine tartrate eye drops, etc.
are temporarily exclusive to Qilu Pharmaceutical Comment.
com, Qilu Pharmaceutical currently has 64 varieties (116 product specifications) passed or deemed to have passed the consistency evaluation.
Among them, 32 varieties are the first domestic companies to be evaluated, and 17 varieties are injections.
In addition, aprepitant capsules, emtricitabine capsules, metformin vildagliptin tablets, warfarin sodium tablets, risperidone orally disintegrating tablets, isoladine maleate tablets, piperacillil capsules, triflux 13 varieties including uridine tipipyrimidine tablets, cefprozil granules, ondansetron hydrochloride tablets, ondansetron hydrochloride injection, exemestane tablets, brimonidine tartrate eye drops, etc.
are temporarily exclusive to Qilu Pharmaceutical Comment.
It is worth mentioning that Qilu Pharmaceutical’s number of over-rated products has long led domestic companies.
The second-ranked China Biopharmaceutical has 57 products (85 product specifications) over-rated, and Yangzijiang Pharmaceutical Group has 55 products (74 products).
Product regulations) ranked third.
The second-ranked China Biopharmaceutical has 57 products (85 product specifications) over-rated, and Yangzijiang Pharmaceutical Group has 55 products (74 products).
Product regulations) ranked third.
With a large group of over-reviewed varieties, Qilu Pharmaceutical has achieved fruitful results in national procurement.
Among the four batches of drug procurement carried out by the country, Qilu Pharmaceutical has won the bids for 5, 4, 8 and 6 varieties respectively, and a total of 23 varieties have won the bid, and the number of winning bids is the largest.
Among the four batches of drug procurement carried out by the country, Qilu Pharmaceutical has won the bids for 5, 4, 8 and 6 varieties respectively, and a total of 23 varieties have won the bid, and the number of winning bids is the largest.
41 new products are on the way, 22 consistency evaluation varieties are under review
With years of hard work in the field of generic drugs, Qilu Pharmaceutical has ushered in an intensive harvest period for new product approvals.
Many varieties in the product line are expected to be approved for listing in the past two years, which will help Qilu Pharmaceutical to firmly sit on the throne of the "first brother in review".
Many varieties in the product line are expected to be approved for listing in the past two years, which will help Qilu Pharmaceutical to firmly sit on the throne of the "first brother in review".
According to data from Minai.
com, Qilu Pharmaceuticals has 41 varieties (73 acceptance numbers) of generic drugs under review under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production.
In terms of supplementary applications for consistency evaluation, Qilu Pharmaceutical has 22 varieties (35 acceptance numbers) under review and approval.
com, Qilu Pharmaceuticals has 41 varieties (73 acceptance numbers) of generic drugs under review under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production.
In terms of supplementary applications for consistency evaluation, Qilu Pharmaceutical has 22 varieties (35 acceptance numbers) under review and approval.
Qilu Pharmaceutical's varieties of consistency evaluation (including new classification) under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
10 varieties are planned to be collected collectively, against Zhengda Tianqing, Yangtze River.
.
.
.
.
On April 15th, the fifth batch of collectively-collected varieties was released, involving 207 varieties of 60 varieties.
Qilu Pharmaceutical, known as the "price killer", has 10 over-reviewed products on the list this time, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglide Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection and ropivacaine hydrochloride injection.
Among them, 8 varieties are injections.
Qilu Pharmaceutical, known as the "price killer", has 10 over-reviewed products on the list this time, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglide Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection and ropivacaine hydrochloride injection.
Among them, 8 varieties are injections.
The competitive landscape of the fifth batch of Qilu Pharmaceuticals to be collected
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Among the 10 varieties, 8 varieties correspond to generic name drugs in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019.
The terminal sales exceeded 1 billion yuan, respectively.
It is oxaliplatin, isosorbide mononitrate, docetaxel, palonosetron, ceftriaxone, ceftazidime, gemcitabine, ropivacaine.
Among them, the terminal sales of docetaxel injection and ceftazidime for injection in China's public medical institutions exceeded 4 billion yuan and 6 billion yuan respectively in 2019.
The terminal sales exceeded 1 billion yuan, respectively.
It is oxaliplatin, isosorbide mononitrate, docetaxel, palonosetron, ceftriaxone, ceftazidime, gemcitabine, ropivacaine.
Among them, the terminal sales of docetaxel injection and ceftazidime for injection in China's public medical institutions exceeded 4 billion yuan and 6 billion yuan respectively in 2019.
Qilu Pharmaceutical's oxaliplatin injection and saxagliptin tablets were approved for production in 2020 and 2021 respectively, and the market is waiting to be developed.
The remaining 8 varieties have been supplemented by consistency evaluation and have been on the market for many years.
The remaining 8 varieties have been supplemented by consistency evaluation and have been on the market for many years.
In terms of competition, 4 companies have reviewed the 3 varieties, 5 companies have reviewed the 5 varieties, and 3 varieties of Zhengda Tianqing and Yangtze River are listed.
In addition, although Qilu Pharmaceutical and Lepu Pharmaceuticals are the only companies that have reviewed isosorbide mononitrate sustained-release tablets, the isosorbide mononitrate sustained-release capsules of Rundu Pharmaceutical and Heyuan Pharmaceutical have also been reviewed.
Generally speaking, the current competition is fierce, and as time goes by, from the publication of the collection catalogue to the opening of bids, there will be many companies reviewing each category.
In addition, although Qilu Pharmaceutical and Lepu Pharmaceuticals are the only companies that have reviewed isosorbide mononitrate sustained-release tablets, the isosorbide mononitrate sustained-release capsules of Rundu Pharmaceutical and Heyuan Pharmaceutical have also been reviewed.
Generally speaking, the current competition is fierce, and as time goes by, from the publication of the collection catalogue to the opening of bids, there will be many companies reviewing each category.
Data source: Mi Neiwang database
Note: The statistics are as of April 15th, if there are any omissions, please correct me!
The fifth batch of collectively-collected varieties was outflowed, involving 60 varieties and 207 product specifications.
Qilu Pharmaceutical has 10 over-rated varieties listed.
On April 14-15, Qilu Pharmaceutical's ropivacaine hydrochloride injection passed the consistency evaluation, and brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved.
At present, Qilu Pharmaceutical ranks first in the evaluation list with 64 varieties.
A large number of varieties are on the way of evaluation.
41 new classification varieties are listed on the market and 22 varieties are under review.
The competition among the 10 varieties to be collected is fierce.
Qilu Pharmaceutical will compete with Zhengda Tianqing, Yangtze River, Hengrui.
.
.
Qilu Pharmaceutical has 10 over-rated varieties listed.
On April 14-15, Qilu Pharmaceutical's ropivacaine hydrochloride injection passed the consistency evaluation, and brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved.
At present, Qilu Pharmaceutical ranks first in the evaluation list with 64 varieties.
A large number of varieties are on the way of evaluation.
41 new classification varieties are listed on the market and 22 varieties are under review.
The competition among the 10 varieties to be collected is fierce.
Qilu Pharmaceutical will compete with Zhengda Tianqing, Yangtze River, Hengrui.
.
.
Take down two major varieties! 64 over-reviewed varieties
Take down two major varieties! 64 over-reviewed varieties On April 14-15, the NMPA official website showed that Qilu Pharmaceutical’s ropivacaine hydrochloride injection passed the consistency evaluation, and two varieties of brimonidine tartrate eye drops and emtricitabine tenofovir tablets were approved for marketing.
.
.
Ropivacaine Hydrochloride Injection is a new long-acting amide local anesthetic developed by AstraZeneca, and it is the leading drug in the local anesthetic market.
According to data from Menet.
com, the sales of terminal ropivacaine injections in public medical institutions in China exceeded 1.
1 billion yuan in 2019.
Prior to this, the ropivacaine hydrochloride injections of Renfu Pharmaceutical, Shisiyao and Jiabo Pharmaceutical have been reviewed.
According to data from Menet.
com, the sales of terminal ropivacaine injections in public medical institutions in China exceeded 1.
1 billion yuan in 2019.
Prior to this, the ropivacaine hydrochloride injections of Renfu Pharmaceutical, Shisiyao and Jiabo Pharmaceutical have been reviewed.
Brimonidine tartrate eye drops have been approved by 3 domestic companies before, but no company has reviewed it.
After the approval of production this time, Qilu Pharmaceutical became the first company to pass the evaluation of this product.
Emtricitabine tenofovir tablets is a blockbuster anti-AIDS drug developed by Gilead, with global sales of 1.
448 billion US dollars in 2020.
There are 4 companies in the domestic market including Gilead, Zhengda Tianqing, Anhui Baker and Haisco Approved, Qilu Pharmaceutical is the fourth domestic manufacturer of this product.
After the approval of production this time, Qilu Pharmaceutical became the first company to pass the evaluation of this product.
Emtricitabine tenofovir tablets is a blockbuster anti-AIDS drug developed by Gilead, with global sales of 1.
448 billion US dollars in 2020.
There are 4 companies in the domestic market including Gilead, Zhengda Tianqing, Anhui Baker and Haisco Approved, Qilu Pharmaceutical is the fourth domestic manufacturer of this product.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, Qilu Pharmaceutical currently has 64 varieties (116 product specifications) passed or deemed to have passed the consistency evaluation.
Among them, 32 varieties are the first domestic companies to be evaluated, and 17 varieties are injections.
In addition, aprepitant capsules, emtricitabine capsules, metformin vildagliptin tablets, warfarin sodium tablets, risperidone orally disintegrating tablets, isoladine maleate tablets, piperacillil capsules, triflux 13 varieties including uridine tipipyrimidine tablets, cefprozil granules, ondansetron hydrochloride tablets, ondansetron hydrochloride injection, exemestane tablets, brimonidine tartrate eye drops, etc.
are temporarily exclusive to Qilu Pharmaceutical Comment.
com, Qilu Pharmaceutical currently has 64 varieties (116 product specifications) passed or deemed to have passed the consistency evaluation.
Among them, 32 varieties are the first domestic companies to be evaluated, and 17 varieties are injections.
In addition, aprepitant capsules, emtricitabine capsules, metformin vildagliptin tablets, warfarin sodium tablets, risperidone orally disintegrating tablets, isoladine maleate tablets, piperacillil capsules, triflux 13 varieties including uridine tipipyrimidine tablets, cefprozil granules, ondansetron hydrochloride tablets, ondansetron hydrochloride injection, exemestane tablets, brimonidine tartrate eye drops, etc.
are temporarily exclusive to Qilu Pharmaceutical Comment.
It is worth mentioning that Qilu Pharmaceutical’s number of over-rated products has long led domestic companies.
The second-ranked China Biopharmaceutical has 57 products (85 product specifications) over-rated, and Yangzijiang Pharmaceutical Group has 55 products (74 products).
Product regulations) ranked third.
The second-ranked China Biopharmaceutical has 57 products (85 product specifications) over-rated, and Yangzijiang Pharmaceutical Group has 55 products (74 products).
Product regulations) ranked third.
With a large group of over-reviewed varieties, Qilu Pharmaceutical has achieved fruitful results in national procurement.
Among the four batches of drug procurement carried out by the country, Qilu Pharmaceutical has won the bids for 5, 4, 8 and 6 varieties respectively, and a total of 23 varieties have won the bid, and the number of winning bids is the largest.
Among the four batches of drug procurement carried out by the country, Qilu Pharmaceutical has won the bids for 5, 4, 8 and 6 varieties respectively, and a total of 23 varieties have won the bid, and the number of winning bids is the largest.
41 new products are on the way, 22 consistency evaluation varieties are under review
41 new products are on the way, 22 consistency evaluation varieties are under review With years of hard work in the field of generic drugs, Qilu Pharmaceutical has ushered in an intensive harvest period for new product approvals.
Many varieties in the product line are expected to be approved for listing in the past two years, which will help Qilu Pharmaceutical to firmly sit on the throne of the "first brother in review".
Many varieties in the product line are expected to be approved for listing in the past two years, which will help Qilu Pharmaceutical to firmly sit on the throne of the "first brother in review".
According to data from Minai.
com, Qilu Pharmaceuticals has 41 varieties (73 acceptance numbers) of generic drugs under review under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production.
In terms of supplementary applications for consistency evaluation, Qilu Pharmaceutical has 22 varieties (35 acceptance numbers) under review and approval.
com, Qilu Pharmaceuticals has 41 varieties (73 acceptance numbers) of generic drugs under review under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production.
In terms of supplementary applications for consistency evaluation, Qilu Pharmaceutical has 22 varieties (35 acceptance numbers) under review and approval.
Qilu Pharmaceutical's varieties of consistency evaluation (including new classification) under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
10 varieties are planned to be collected collectively, against Zhengda Tianqing, Yangtze River.
.
.
10 varieties are planned to be collected collectively, against Zhengda Tianqing, Yangtze River. .
.
.
.
On April 15th, the fifth batch of collectively-collected varieties was released, involving 207 varieties of 60 varieties.
Qilu Pharmaceutical, known as the "price killer", has 10 over-reviewed products on the list this time, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglide Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection and ropivacaine hydrochloride injection.
Among them, 8 varieties are injections.
Qilu Pharmaceutical, known as the "price killer", has 10 over-reviewed products on the list this time, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, and saxaglide Tine tablets, fasudil hydrochloride injection, palonosetron hydrochloride injection, ceftriaxone sodium for injection, ceftazidime for injection, gemcitabine hydrochloride for injection and ropivacaine hydrochloride injection.
Among them, 8 varieties are injections.
The competitive landscape of the fifth batch of Qilu Pharmaceuticals to be collected
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Among the 10 varieties, 8 varieties correspond to generic name drugs in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2019.
The terminal sales exceeded 1 billion yuan, respectively.
It is oxaliplatin, isosorbide mononitrate, docetaxel, palonosetron, ceftriaxone, ceftazidime, gemcitabine, ropivacaine.
Among them, the terminal sales of docetaxel injection and ceftazidime for injection in China's public medical institutions exceeded 4 billion yuan and 6 billion yuan respectively in 2019.
The terminal sales exceeded 1 billion yuan, respectively.
It is oxaliplatin, isosorbide mononitrate, docetaxel, palonosetron, ceftriaxone, ceftazidime, gemcitabine, ropivacaine.
Among them, the terminal sales of docetaxel injection and ceftazidime for injection in China's public medical institutions exceeded 4 billion yuan and 6 billion yuan respectively in 2019.
Qilu Pharmaceutical's oxaliplatin injection and saxagliptin tablets were approved for production in 2020 and 2021 respectively, and the market is waiting to be developed.
The remaining 8 varieties have been supplemented by consistency evaluation and have been on the market for many years.
The remaining 8 varieties have been supplemented by consistency evaluation and have been on the market for many years.
In terms of competition, 4 companies have reviewed the 3 varieties, 5 companies have reviewed the 5 varieties, and 3 varieties of Zhengda Tianqing and Yangtze River are listed.
In addition, although Qilu Pharmaceutical and Lepu Pharmaceuticals are the only companies that have reviewed isosorbide mononitrate sustained-release tablets, the isosorbide mononitrate sustained-release capsules of Rundu Pharmaceutical and Heyuan Pharmaceutical have also been reviewed.
Generally speaking, the current competition is fierce, and as time goes by, from the publication of the collection catalogue to the opening of bids, there will be many companies reviewing each category.
In addition, although Qilu Pharmaceutical and Lepu Pharmaceuticals are the only companies that have reviewed isosorbide mononitrate sustained-release tablets, the isosorbide mononitrate sustained-release capsules of Rundu Pharmaceutical and Heyuan Pharmaceutical have also been reviewed.
Generally speaking, the current competition is fierce, and as time goes by, from the publication of the collection catalogue to the opening of bids, there will be many companies reviewing each category.
Data source: Mi Neiwang database
Note: The statistics are as of April 15th, if there are any omissions, please correct me!
